Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CM 536

Next Previous
Drug Profile

CM 536

Alternative Names: BEL-536; CM-536

Latest Information Update: 26 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KeyMed Biosciences
  • Developer Belenos Biosciences; KeyMed Biosciences
  • Class Anti-inflammatories; Bispecific antibodies; Immunotherapies
  • Mechanism of Action OX40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 10 Nov 2025 Belenos Biosciences plans to initiate phase I trial of CM 536 in Inflammation in Q1 2026
  • 27 Aug 2024 CM 536 licensed to Belenos Biosciences worldwide excluding China
  • 27 Aug 2024 Preclinical trials in Inflammation in China (Parenteral) prior to August 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top